Discovery of (phenoxy-2-hydroxypropyl)piperidines as a novel class of voltage-gated sodium channel 1.7 inhibitors

Bioorg Med Chem Lett. 2015 Nov 15;25(22):5419-23. doi: 10.1016/j.bmcl.2015.09.005. Epub 2015 Sep 5.

Abstract

A novel class of NaV1.7 inhibitors has been identified by high-throughput screening followed by structure activity relationship studies. Among this series of compounds, piperidine 9o showed potent human and mouse NaV1.7 inhibitory activities with fair subtype selectivity over NaV1.5. Compound 9o successfully demonstrated analgesic efficacy in mice comparable to that of the currently used drug, mexiletine, but with an expanded central nervous system safety margin.

Keywords: CNS side effects; High-throughput screening; Pain; Piperidine; Voltage-gated sodium channel.

MeSH terms

  • Animals
  • Drug Discovery*
  • Humans
  • Inhibitory Concentration 50
  • Mexiletine / chemistry
  • Mexiletine / pharmacology
  • Mice
  • Molecular Structure
  • NAV1.7 Voltage-Gated Sodium Channel / drug effects*
  • Piperidines / chemical synthesis*
  • Piperidines / chemistry
  • Piperidines / pharmacology*
  • Voltage-Gated Sodium Channel Blockers / chemical synthesis*
  • Voltage-Gated Sodium Channel Blockers / chemistry
  • Voltage-Gated Sodium Channel Blockers / pharmacology*

Substances

  • NAV1.7 Voltage-Gated Sodium Channel
  • Piperidines
  • Voltage-Gated Sodium Channel Blockers
  • Mexiletine
  • piperidine